MedTrace Logo

Effectiveness of Phenazopyridine for Pain Following Urodynamics

NCT06577493 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2026-04-29

No results posted yet for this study

Summary

The purpose of the study is to determine if taking phenazopyridine (AZO) at the time of urodynamic study testing will decrease pain experienced by patients after undergoing urodynamic testing.

Conditions

  • Pain After Urodynamic Testing

Interventions

DRUG

Phenazopyridine Hydrochloride 99.5 MG

Experimental arm to take two 99.5 mg phenazopyridine hydrochloride by mouth for a total of 199mg immediately prior to start of urodynamic testing

Sponsors & Collaborators

  • University of South Florida

    lead OTHER

Principal Investigators

  • Elizabeth A Wilkinson, MD · University of South Florida

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-12-17
Primary Completion
2025-11-24
Completion
2026-07-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06577493 on ClinicalTrials.gov